Squarepoint Ops LLC Purchases New Holdings in Beta Bionics, Inc. $BBNX

Key Points

• Squarepoint Ops LLC acquired 161,098 Beta Bionics shares during the second quarter, worth approximately $2.52 million and representing a 0.36% stake. Several other institutional investors also initiated or increased positions.
• Beta Bionics reported quarterly revenue of $32.01 million and an adjusted loss of $0.53 per share, beating the consensus estimate of a $0.62 loss. The stock opened at $16.73, with a market capitalization of about $752.7 million.
• Analyst sentiment remains favorable, with a consensus rating of “Moderate Buy” and an average price target of $20.40. However, insiders have sold 70,132 shares worth about $1.28 million over the past 90 days.

Squarepoint Ops LLC acquired a new position in Beta Bionics, Inc. (NASDAQ:BBNX - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 161,098 shares of the company's stock, valued at approximately $2,524,000. Squarepoint Ops LLC owned 0.36% of Beta Bionics as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd raised its stake in Beta Bionics by 1,075.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company's stock valued at $61,000 after purchasing an additional 1,818 shares during the period. Legal & General Group Plc acquired a new stake in shares of Beta Bionics in the second quarter worth $62,000. California State Teachers Retirement System grew its holdings in shares of Beta Bionics by 306.1% during the second quarter. California State Teachers Retirement System now owns 8,556 shares of the company's stock valued at $134,000 after buying an additional 6,449 shares in the last quarter. ProShare Advisors LLC purchased a new position in shares of Beta Bionics during the fourth quarter valued at $217,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Beta Bionics during the second quarter valued at $172,000.

Beta Bionics Trading Up 1.0%

NASDAQ BBNX opened at $16.73 on Tuesday. Beta Bionics, Inc. has a 1-year low of $8.80 and a 1-year high of $32.71. The firm's fifty day simple moving average is $17.30 and its 200-day simple moving average is $13.82. The company has a market capitalization of $752.68 million, a PE ratio of -10.14 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%.The firm had revenue of $32.01 million during the quarter. As a group, analysts predict that Beta Bionics, Inc. will post -2.1 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Leerink Partners increased their price objective on Beta Bionics from $24.00 to $27.00 and gave the stock an "outperform" rating in a research note on Monday. Weiss Ratings raised Beta Bionics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, August 18th. The Goldman Sachs Group upped their target price on Beta Bionics from $17.00 to $19.00 and gave the company a "buy" rating in a report on Wednesday, July 15th. William Blair initiated coverage on shares of Beta Bionics in a research report on Friday, August 21st. They issued a "market perform" rating for the company. Finally, UBS Group began coverage on shares of Beta Bionics in a report on Tuesday, July 28th. They set a "buy" rating and a $22.00 price target for the company. Seven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $20.40.

Insider Transactions at Beta Bionics

In other news, insider Steven Russell sold 4,221 shares of Beta Bionics stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $80,663.31. Following the completion of the sale, the insider directly owned 169,628 shares in the company, valued at $3,241,591.08. The trade was a 2.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mark Hopman sold 36,870 shares of the business's stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $18.46, for a total value of $680,620.20. Following the completion of the sale, the insider directly owned 87,157 shares of the company's stock, valued at approximately $1,608,918.22. The trade was a 29.73% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 70,132 shares of company stock valued at $1,284,623 over the last 90 days. Company insiders own 5.30% of the company's stock.

More Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: The FDA cleared Mint, Beta Bionics’ new insulin patch pump. Its reusable-and-disposable design does not require recharging, supports leading continuous glucose monitors, and allows smartphone control on iOS and Android. The product is expected to expand Beta Bionics’ addressable market, with a planned 2027 launch. Beta Bionics Announces FDA Clearance of Mint
• Positive Sentiment: Beta Bionics also unveiled 3D Intelligence, its next-generation insulin-dosing algorithm, potentially strengthening the company’s technology platform and competitive positioning in automated diabetes care. Beta Bionics Announces Mint and 3D Intelligence
• Positive Sentiment: The company formed a partnership with Senseonics to integrate the year-long Eversense 365 continuous glucose monitor with the iLet Bionic Pancreas. The combined system is targeted for commercial launch in the fourth quarter of 2026, which could improve product functionality and adoption. Senseonics Partnership with Beta Bionics
• Negative Sentiment: Beta Bionics lowered its 2026 revenue guidance, signaling weaker near-term sales expectations despite the Mint clearance. The reduced outlook may limit investor confidence and offset some of the product-related optimism. Beta Bionics Lowers 2026 Revenue Guidance
• Negative Sentiment: Several law firms announced or promoted securities-fraud litigation involving Beta Bionics. The complaints allege iLet safety, FDA-compliance, and customer-complaint-handling issues; the allegations have not been proven. Continued legal news creates reputational, financial, and regulatory overhang for BBNX. Beta Bionics Securities Fraud Class Action

Beta Bionics Profile

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.